Opportunity: The Gene Synthesis Software Market represents a cutting-edge opportunity in the biotechnology and genomics field. As the demand for custom-designed DNA sequences and genetic constructs ...

Company engaging in multiple options for a constructive resolution Strategy is underpinned by a clinical study that achieved the agreed upon endpoints Company believes that labeling modifications can ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for ...

Support for Xilinx's low-cost, high-volume Spartan-3A family of I/O-optimized FPGAs is now offered by Synplicity's Synplify Pro FPGA synthesis software. The Synplify Pro FPGA synthesis tool helps ...

HeartBeam has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram (ECG) synthesis software tailored to assess various cardiac rhythms and ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...

HeartBeam (NASDAQ: BEAT) was among the medical device companies highlighted in a Jan. 8 report by Modern Healthcare by ...